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Abstract
Background: Fatigue is the most frequent symptom reported by patients with chronic illnesses. As a subjective
experience, fatigue is commonly assessed with patient-reported outcome measures (PROMs). Currently, there are more
than 40 generic and disease-specific PROMs for assessing fatigue in use today. The interpretation of changes in PROM
scores may be enhanced by estimates of the so-called minimal important difference (MID). MIDs are not fixed attributes
of PROMs but rather vary in relation to estimation method, clinical and demographic characteristics of the study group,
etc. The purpose of this paper is to compile published MIDs for fatigue PROMs, spanning diagnostic/patient groups and
estimation methods, and to provide information relevant for appraising their appropriateness for use in specific clinical
trials and in monitoring fatigue in defined patient groups in routine clinical practice.
Methods: A systematic search of three databases (Scopus, CINAHL and Cochrane) for studies published between January
2000 to April 2015 using fatigue and variations of the term MID, e.g. MCID, MIC, etc. Two authors screened search hits
and extracted data independently. Data regarding MIDs, anchors used and study designs were compiled in tables.
Results: Included studies (n = 41) reported 60 studies or substudies estimating MID for 28 fatigue scales, subscales or
single item measures in a variety of diagnostic groups and study designs. All studies used anchor-based methods, 21/60
measures also included distribution-based methods and 17/60 used triangulation of methods. Both similarities and
dissimilarities were seen within the MIDs.
Conclusions: Magnitudes of published MIDs for fatigue PROMs vary considerably. Information about the derivation of
fatigue MIDs is needed to evaluate their applicability and suitability for use in clinical practice and research.
Keywords: MID, Fatigue, PROM, Minimal important difference, Systematic review, MCID, MCII
Background
Fatigue is among the most frequent complaints reported by
patients with chronic illnesses [1–4] and has far-ranging,
often debilitating consequences on their wellbeing and
physical, emotional and social functioning [5]. Although
there is no consensus definition of fatigue, it is often de-
scribed as ‘a persistent, overwhelming sense of tiredness,
weakness or exhaustion resulting in a decreased capacity
for physical and⁄or mental work [6]. Fatigue is a subjective
experience and is commonly assessed by means of patient-
reported outcome measures (PROMs). PROMs are widely
used today in evaluating the effects of illness and treatment
on symptoms, functioning, and other outcomes from the
patient’s perspective [7].
Currently, there are some 40 generic and disease-specific
PROMs for assessing fatigue in use today [8]. Most of these
fatigue measures have been evaluated regarding various as-
pects of validity and reliability. Although these are import-
ant psychometric properties reflecting the quality of the
measure, they are of little value in interpreting the meaning
of scores derived from that measure [9]. Nonetheless, in-
terpretation of scores, in particular changes in scores, is of
critical concern in trials evaluating effects of treatments
aimed at reducing fatigue, as well as in routine clinical
practice in monitoring and managing fatigue in individual
* Correspondence: anna.dencker@gu.se
1Gothenburg Centre for Person-Centred Care (GPCC), Sahlgrenska Academy,
University of Gothenburg, Gothenburg, Sweden
3Institute of Health and Care Sciences, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nordin et al. BMC Medical Research Methodology  (2016) 16:62 
DOI 10.1186/s12874-016-0167-6
patients. In clinical trials, it has long been recognized that
conventional statistical significance testing provides infor-
mation regarding the probability that an effect exists, not
about the meaningfulness of the size of the effect [10]. In
clinical practice, difficulties in evaluating and interpreting
changes in PROM scores often impinge on their usefulness
in informing clinical decision-making [11].
The interpretation of changes in PROM scores may be
enhanced by estimates of the so-called minimal import-
ant difference (MID). MID was originally defined over
25 years ago as “the smallest difference in score in the
domain of interest which patients perceive as beneficial
and which would mandate, in the absence of troublesome
side effects and excessive cost, a change in the patient’s
management” [12]. During the past decades considerable
research attention has been directed towards deriving MIDs
for PROMS. In this pursuit a variety of methods have been
developed and applied, but no clear consensus exists re-
garding which method or methods are most suitable.
To date, two main methods have been applied, namely
anchor-based approaches and distribution-based ap-
proaches. Descriptions of these methods are beyond the
scope of this paper and are summarized in detail else-
where [13]. Briefly, anchor-based approaches use various
external criteria (patient-reported, physician-reported, or
clinical anchors) to interpret whether a particular magni-
tude of change is important. For example, a common
anchor-based method involves the use of global rating
scales (GRS) where MIDs are derived by comparing pa-
tients’ self-ratings of change (e.g., “much worse”—“much
better”) to change in PROM scores. The MID is often
defined as lying within the range of “slightly worse/better”
on the GRS [9]. Distribution-based approaches rely on the
statistical characteristics of the distribution of scores in
the sample, in which the magnitude of change is generally
expressed as a function of the standard deviation (SD) of
scores alone or in combination with the reliability of the
PROM (standard error of the measurement (SEM)) [14].
Various SD and SEM cut-off values have been proposed
for estimating MIDs, including ½ or 1/3 SD and 1–2
SEM. Another commonly applied method is the use of ef-
fect sizes (ES) or standardized response means (SRM),
where change scores are divided by the SD at baseline or
the SD of change, respectively. The MID is often defined
as change values lying within the range of 0.2-0.5. A
disadvantage to distribution-based approaches is that they
do not address the clinical importance of the change.
Recent recommendations have proposed that as a first-
line method multiple anchor-based approaches should be
used, which, supported by distribution-based methods,
may be triangulated to a single MID value or smaller
range of values [14–17].
Although appealing for its simplicity, the idea of a sin-
gle, universal MID value for any particular PROM remains
elusive for a number of reasons. Firstly, different MID
estimation approaches have been shown to yield highly
disparate MIDs and hence triangulation (combining dif-
ferent methods to estimate a MID) may be problematic
[18]. Secondly, MIDs have also been shown to differ by
population and context [14]. For example, MIDs vary
by diagnostic group, characteristics of the study sample,
e.g., demographics and baseline levels; disease severity;
treatment; choice of anchors [18, 19] as well as if MIDs
gauge improvement versus deterioration [20]. This vari-
ability suggests the need to understand how a particular
MID value was determined in order to judge its appro-
priateness for use in research for interpreting change
and/or computing sample sizes, or in clinical practice
for monitoring fatigue in specific patient groups [21].
The purpose of this paper is to compile published
MIDs for fatigue PROMs, spanning diagnostic/patient
groups and estimation methods, and to provide informa-
tion relevant for appraising their appropriateness for use
in specific clinical trials and in monitoring fatigue in de-
fined patient groups in routine clinical practice.
Methods
A systematic literature review where three databases
(Scopus, CINAHL and Cochrane) were searched from
January 2000 to April 2015 to identify studies with
calculated MIDs in fatigue scales, subscales and single
item measures. The searches were limited to English
language (search string: “minimal clinical important
difference*” OR “minimal important difference*” OR
“minimal clinically important difference*” OR “minimally
important difference*” OR “clinical important improve-
ment*” OR “clinically important improvement*” OR
“minimal important clinical difference*” OR “minimally
important clinical difference*” OR ”responder defin-
ition”) AND Fatigue). The search was augmented with
screening of article reference lists. All expressions in-
cluding “difference/change/improvement” or equiva-
lent, “important” as well as “minimal” or “clinical”, or
“responder definition” were defined as MIDs. To facili-
tate the reading all minimally important changes are
called MIDs in this paper.
Selection of articles
Inclusion criteria were reporting MIDs in text and/or
tables for a fatigue scale, subscale or single item measure-
ment of fatigue. Exclusion criteria were: reported MID
was not derived directly in the study; insufficient informa-
tion supplied about the study sample, study design and/or
method for determining the MID; study sample < 18 years,
not separate reporting of MIDs for a fatigue subscale and
conference abstracts. Exclusion on title/abstract and on
full-text levels were done independently by two researchers
(ÅN and AD), see Fig. 1.
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Data extraction
Two authors (ÅN and AD) extracted data regarding MIDs
and methods used, including anchors used. The last
author (AD) checked all data extraction and prepared
the tables. To facilitate interpretation all MIDs are shown
as absolute values and decimals are restricted to one sig-
nificant number only, except for effect sizes. Some studies
reported standard deviation (SD) and confidence intervals
but these are not shown in our tables or text. The fatigue
measurements were identified as multidimensional scales,
unidimensional scales or subscales, single item measure-
ment or item bank scales.
Results
The literature search generated 177 articles (Fig. 1), of
which 41 met the inclusion criteria [22–62]. The main
reasons for exclusion were: reported MID was not derived
in the study; and inadequate information was supplied
about the study sample, study design and/or method for
determining the MID. Many different expressions were
used to name a small but important change in fatigue
[13]. In this review we included studies using different
phrases for MID (see Table 1), e.g. “MID”, “MCID”,
“MCII” or an equivalent expression, all referred to as MID
in this paper. Most of these expressions used some vari-
ation of “difference/change/improvement” or equivalent,
“important” as well as “minimal”. Some phrases also in-
cluded “clinical”. Two studies used “responder definition”
[43, 55], see Table 1. In two systematic reviews a phrase
without “minimal” was used [59, 60] but the authors de-
fined values for a small or minimal change.
The included articles (n = 41) reported MIDs for 28
fatigue PROMs (characteristics shown in Table 2), result-
ing in 60 studies/substudies of MIDs. The studies varied
in sample size, diagnostic group, MID estimation ap-
proach, study design, type of intervention and length of
follow up. Sample sizes ranged from n = 40 to n = 2,583.
Sixteen different diagnoses were included in the reviewed
studies. Twenty-seven of the studies in the 41 articles were
longitudinal and follow-up periods ranged from two days
after intervention to one year after baseline. An anchor-
based approach alone was used in 39 of the 60 studies or
substudies estimating MID, while the rest also used a
distribution-based approach. Seventeen of these also in-
cluded a method of triangulation to define MIDs. Two
cross-sectional studies [33, 46] reported MIDs for seven
fatigue or vitality scales (MFI, FSS, MAF, CFS, VT/SF-36,
FACIT-F and GRS). Other studies determined MIDs for
two or more fatigue measures or subscales [28, 47, 48, 51,
59–61]. Several PROMs had MIDs determined in a num-
ber of different studies and several studies reported MIDs
for up to seven PROMs. Nevertheless, most MIDs were
derived in single studies, with one study per PROM
[22–27, 29–32, 34–43, 45, 49, 50, 52–58, 62], see
Table 3. Altogether, 60 studies or substudies estimating
MIDs for global change (not specified direction of change),
improvement and/or deterioration are described in Table 3.
In Table 3 all score changes are presented as positive values,
regardless of the direction of change. Confidence intervals
and SDs (if derived in study) are not shown. Numbers are
rounded to one decimal place.
Multidimensional scales
Multidimensional fatigue inventory (MFI), score 20–100
Two cross-sectional studies [33, 46] derived MIDs for
systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) populations for the MFI total scale,
using a patient global rating scale and interviews as
anchors. MIDs ranged from 11.5 to 13.3 for global
change and 6.8 to 9.6 for improvement and 9.5 and
12.8 for deterioration.
Fatigue severity scale (FSS), score 1–7
Three cross-sectional studies reporting MIDs for the
FSS were identified [33, 46, 50]. Diagnostic groups in-
cluded SLE, RA and multiple sclerosis (MS). Anchor-
based approaches were applied in all the three studies
and a distribution-based approach (viz. effect size, ES, of
at least 0.25) was also applied in one [50]. Two used a
patient global rating scale as an anchor [33, 46] whereas
the third used clinical anchors and baseline data from a
clinical trial to establish MIDs [50] MIDs ranged from
0.5 to 1.2 for global change, 0.08 to 0.4 for improvement
and 1.0 to 1.2 for deterioration.
Multidimensional assessment of fatigue (MAF), score 1–50
MID-estimates for the MAF in two cross-sectional
studies with SLE and RA patients [33, 46] were estimated
to 5.0 and 9.2 for global change, 1.4 to 5.4 for improve-
ment and 8.3 to 8.9 for worsening, using a patient global
rating scale.
Potentially relevant publications identified and screened for retrieval 
n = 177
Publications excluded on the basis of duplication, n = 25
Publications excluded on the basis of title or abstract, 
n = 79
Full text publications retrieved for more detailed evaluation, n = 73
Publications excluded after full-text screening, n = 32
Publications included in the review, n = 41
Fig. 1 Flowchart of selection of articles to include
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Table 1 Included articles with reported fatigue MIDs, n = 41
First author/country Instrument/scale Term useda
Baró et al. 2011 [22]
Spain
Perform Questionnaire Minimally important difference, MID
Bedard et al. 2013a [23]
Canada
ESAS fatigue item Minimal clinically important difference, MCID
Bedard et al. 2013b [24]
Canada
EORTC QLQ-30—Fatigue Scale Minimal important difference, MID
Bedard et al. 2014 [25]
Canada
EORTC QLQ-30—Fatigue Scale Minimal important difference, MID
Bjorner et al. 2007 [26]
USA, MOS-study
VT/SF-36 Minimally important difference, MID
Borghs et al. 2012 [27]
Belgium
QOLIE-3 Energy/fatigue subscale Minimally important change, MIC
Cella et al. 2002 [28]
USA
FACIT-Fatigue TOI-F Minimal clinically important difference, CID
(MCID in short title)
Cella et al. 2005 [29]
USA
FACT-Fatigue Minimally important difference, MID
Colangelo et al. 2009 [30]
Canada
Fatigue VAS (0–100) Minimally important difference, MID
de Kleijn et al. 2011 [31]
Netherlands
FAS Minimal (clinically) important difference, MCID
George & Pope 2011 [32]
Canada
VAS fatigue (0–100) Minimal important difference, MID
Goligher et al. 2008 [33]
Canada
MFI, FSS, MAF, CFS, FACIT-F, VT/SF-36, GRS Minimal important difference, MID
Khanna et al. 2008 [34]
Canada
Fatigue VAS (0–10) Minimally important difference, MID
Kosinski et al. 2000 [35]
USA
VT/SF-36 Minimally important change, MIC
Kvam et al. 2010 [36]
Norway
EORTC QLQ-C30 Fatigue Subscale Minimal important difference, MID
Kwok and Pope 2010 [37]
Canada
Fatigue VAS (0–100) Minimally important difference, MID
Lai et al. 2011 [38]
USA
FACIT-Fatigue subscale Minimally important difference, MID
Lasch et al. 2009 [39]
USA
SIS Energy/Fatigue and Mental Fatigue subscales Minimum important difference, MID
Maringwa et al. 2011a [40]
17 countries
EORTC QLQ-C30 Fatigue Subscale Minimal clinically important difference, MCID
Maringwa et al. 2011b [41]
12 countries
EORTC QLQ-C30 Fatigue Subscale Minimal important difference, MID
Mathias et al. 2009 [42]
USA and Europe
ITP-PAC Minimally important difference, MID
Matza et al. 2013 [43]
USA
FAsD Responder definition
Mills et al. 2012 [44]
UK
NFI-MS Minimum clinically important difference, MCID
Patrick et al. 2003 [45]
USA
FACT-An fatigue subscale Minimally important difference, MID
Pouchot et al. 2008 [46]
Canada
MFI, FSS, MAF, CFS, FACIT-F, VT/SF-36, GRS Minimal clinically important difference, MCID
Purcell et al. 2010 [47]
Australia
MFI subscales Minimal clinically importantdifference, MCID
Reddy et al. 2007 [48]
USA
FACIT-Fatigue subscale ESAS fatigue item Clinically important improvement
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Chalder fatigue scale (CFS), score 0–33
The same two cross-sectional studies [33, 46] reported
MIDs for the CFS where MIDs for global change were 2.3–
3.3; for improvement 0.7–1.4; and for deterioration 3.2–3.5.
Fatigue impact scale (FIS), score 0–160
One cross-sectional study with MS patients [49] reported
MIDs for the FIS ranging from 9–24 points for the differ-
ent patient and clinician rating anchors, with a mean of
15.5 and SD 4.9. Distribution-based methods yielded MIDs
ranging between 4.8–17.3 (1–2 SEM; ± 1/3-1/2 SD).
Triangulation of anchor and distribution-based methods
gave a MID range of 10–20 points.
Trial outcome index-fatigue (TOI-F), score 0–108
One study [28] reported TOI-F MIDs using data from
three separate cancer trials. Triangulation was used to
determine a MID, combining a patient-reported anchor,
two physician-reported anchors (including response to
treatment ratings), and one clinical anchor (haemoglobin
level). MID estimates ranged from 4.8 to 26.6, and a sin-
gle triangulated MID of 5.0 was recommended.
Perform questionnaire (PQ), score 12–60
One longitudinal study [22] estimated the PQ MID in
cancer patients to be 3.7 for improvement. Triangulation
was used to estimate a recommended MID of 3.5.
Schwartz cancer fatigue scale (SCFS), score 3–30
A longitudinal study of the SCFS using a patient-rated
anchor [51] reported MIDs for global change was 5.0;
for improvement 2.1; and for deterioration 5.7 after a
two days follow-up.
Fatigue associated with depression questionnaire (FAsD),
score 1–5
MIDs for the FAsD were estimated in one longitudinal
study [43] of patients with a clinical diagnosis of depres-
sion ranging from 0.3 to 0.6 for improvement and 0.2–0.3
for worsening after 6 weeks follow-up.
Neurological fatigue index for multiple sclerosis (NFI-MS),
summary score 0–30
One longitudinal study [44] using a patient global as-
sessment of change reported MIDs for the NFI-MS; 2.5
for the ten-item Summary scale, 2.4 for the Physical
scale (score range 0–24) and 0.8 for the Cognitive scale
(score range 0–12).
Unidimensional scales or subscales
Multidimensional fatigue inventory (MFI) subscales, score 4–20
A longitudinal study [47] derived MIDs in a cancer
population (pre and post radiotherapy) for the MFI five
subscales. MIDs ranged between 1.4 to 2.4 depending on
Table 1 Included articles with reported fatigue MIDs, n = 41 (Continued)
Rendas-Baum et al. 2010 [49]
Canada
FIS Minimally important difference, MID
Robinson et al. 2009 [50]
USA
FSS Minimally important difference, MID
Schwartz et al. 2002 [51]
USA
SCFS, POMS-F, single item Minimally important clinical difference, MICD
Schünemann et al. 2005 [52] CRQ/Fatigue subscale Minimal important difference, MID
Sekhon et al. 2010 [53]
Canada
Fatigue VAS (0–100) Minimally important difference, MID
Spiegel et al. 2005 [54] VT/SF-36 Minimally clinically important difference, MCID
Twiss et al. 2010 [55]
8 countries
U-FIS Responder definition, RD
Ward et al. 2015 [56]
USA
VT/SF-36 Minimal clinically important improvement, MCII
Wells et al. 2007 [57]
USA
Fatigue VAS (0–100) Minimal clinically important difference, MCID
Wheaton & Pope 2010 [58]
Canada
Fatigue VAS (0–100) Minimal important difference, MID
Wyrwich et al. 2003 [59] VT/SF-36 CRQ/Fatigue subscale Clinically important difference, CID
Wyrwich et al. 2004 [60] VT/SF-36 CHQ/Fatigue subscale Clinically important difference, CID
Yost et al. 2011 [61]
USA
PROMIS Fatigue (Fatigue-17, Fatigue-7) Minimally important difference, MID
Zeng et al. 2012 [62]
7 countries
EORTC QLQ-C30 Fatigue Subscale Minimal clinically important difference, MCID
aAll expressions in this column are referred to as “MID” in the current study
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subscale. A general MID for all MFI subscales was rec-
ommended corresponding to 2 points.
Unidimensional fatigue impact scale (U-FIS), score 0–66
One longitudinal study using EQ5D as an anchor
[55] derived MIDs in an MS sample. U-FIS MIDs
corresponded to 6.5 for improvement and 4.7 for
deterioration, and distribution-based MIDs between
2.4 and 7.0.
Fatigue assessment scale (FAS), score 10–50
MIDs for the FAS were reported in one longitudinal
study of sarcoidosis patients using WHOQOL-BREF/
Physical health domain and a ROC-curve as anchors as
Table 2 Overview of reviewed fatigue scales, subscales and single fatigue item with published MIDs, n = 28
Name of PROM Abbreviated name Number
of items
Score range Characteristics of scale
Chalder Fatigue Scale CFS 14 0–33 Multidimensional
Chronic Heart Failure Questionnaire, Fatigue subscale CHQ 4 1–7 Unidimensional subscale
Negative scorea
Chronic Respiratory Questionnaire, Fatigue subscale CRQ 4 1–7 Unidimensional subscale
Negative scorea
Edmonton Symptom Assessment System, Fatigue item ESAS Fatigue item 1 0–10 Single item
European Organization for Research and Treatment




3 0–100 Unidimensional subscale
FACIT-Fatigue Scale FACIT-Fatigue 13 0–52 Unidimensional scale/subscale,
Negative scorea
FACT-An, Fatigue subscale FACT-An Fatigue 20 0–80 Unidimensional subscale
Fatigue Assessment Scale FAS 10 10–50 Unidimensional
Fatigue Associated with Depression Questionnaire FAsD 13 1–5 Multidimensional
Fatigue Impact Scale FIS 40 0–160 Multidimensional
Fatigue Severity Scale FSS 9 1–7 Multidimensional
Global RS GRS 1 0–10 Single item
Immune thrombocytopenic Purpura –Patient
Assessment Questionnaire, Fatigue subscale
ITP-PAC 1 0–100 Single item
Multidimensional Assessment of Fatigue MAF 16 1–50 Multidimensional
Multidimensional Fatigue Inventory MFI 20 20–100 (4–20 in
each subscale)
Multidimensional, (5 subscales:
GF, PF, RA, RM and MF)b
Neurological Fatigue Index for multiple sclerosis NFI-MS 12 0–30 in SS, 0–24 in
PS and 0–12 in CS
Multidimensional,
(3 scales: SS, PS and CS)c
Perform Questionnaire PQ 12 12–60 Multidimensional, Negative scorea
Profile of Mood States-Fatigue POMS-F 7 0–28 Unidimensional subscale
PROMIS Fatigue-17 Fatigue-17 17 17–85 Unidimensional
PROMIS Fatigue-7 Fatigue-7 7 7–35 Unidimensional
Quality of Life Inventory in Epilepsy,
Energy/Fatigue subscale
QOLIE-31 4 0–100 Unidimensional subscale
Negative scorea
Schwartz Cancer Fatigue Scale SCFS 6 6–30 Multidimensional
SF-36 Vitality scale SF-VT 4 0–100 Unidimensional subscale
Sleep Impact Scale, Energy/Fatigue (E/F),





Trial Outcome Index-Fatigue TOI-F 27 0–108 Multidimensional, Negative scorea
Unidimensional Fatigue Impact Scale U-FIS 22 0–66 Unidimensional
Visual Analogue Scale 0–10 VAS 0–10 1 0–10 Single item
Visual Analogue Scale 0–100 VAS 0–100 1 0–100 Single item
aNegative score = high values indicate low level of fatigue
bGF General fatigue, PF Physical fatigue, RA Reduced activity, RM Reduced motivation. MF Mental fatigue
cSS Summary scale, PS Physical scale and CS Cognitive scale
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Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons
11.5 (14 %) 9.6 12.8
Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons
13.3 (17 %) 6.8 9.5
FSS
(1–7)
Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons
0.6 (10 %) 0.08 1.2
Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons
1.2 (20 %) 0.4 1.0
Robinson et al. 2009
MS (n = 249)
Cross-sectional Disease duration, Expanded Disability
Status Scale, Patient Assessment of MS
Impact, MS Functional Composite
0.5–1.1 (8–18 %) ES 0.3–0.8 1
MAF
(1–50)
Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons
5.0 (10 %) 1.4 8.9
Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons
9.2 (19 %) 5.4 8.3
CFS
(0–33)
Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons
2.3 (7 %) 0.7 3.2
Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons




2010 MS (n = 184)











Cella et al. 2002




up: 3 d - 12 m
Performance status, haemoglobin level,
response to treatment





Baró et al. 2011
Cancer (n = 437)
Longitudinal
Follow-up: 3 m
Haemoglobin level 3.7 3.5
SCFS
(6–30)
Schwartz et al. 2001
Cancer (n = 103)
Longitudinal
Follow-up: 2 d
GRS (7-step) 5.0 (21 %) 2.1 5.7
FAsD
(1–5)
Matza et al. 2013
Depression (n = 96)
Longitudinal
Follow-up: 6 w






Mills et al. 2012
MS (n = 208)
Longitudinal
Follow-up: 6–8 w
Global perceived change item (5-step) 2.5 (SS) (8 %)
2.4 (PS) (10 %)















Table 3 Studies/substudies (n = 60) with reported MIDs for fatigue scales, subscales or single fatigue items. Study design and population are shown along with estimation
method (Continued)
Unidimensional scales or subscales
MFI sbscales: GF,
PF, RA, RM and MF
(4–20)
Purcell et al. 2010




Score change pre- and post-radiotherapy GF: 2.1 (13 %)
PF: 2.0 (13 %)
RA: 2.4 (15 %)
RM: 1.6 (10 %)





Twiss et al. 2010
MS (n = 911)
Longitudinal
Follow-up: 12 m





de Kleijn et al. 2011
Sarcoidosis (n = 321)
Longitudinal
Follow-up: 12 m





Bjorner et al. 2007
Several disease
conditions (n = 3,445)
Cross-sectional Regression analyses using age, gender, race,
disease condition and functional outcomes
5/group level
10/individual level
Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons
10.7 (11 %) 7.3 18.3
Kosinski et al. 2000
RA (n = 693)
Longitudinal
Follow-up: 6 w
Patient global assessment, Physician global
assessment, pain, swelling, tenderness
4.9–11.1
(5–11 %)
Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons
14.8 (15 %) 11.3 11.9









Ward et al. 2015
RA (n = 249)
Longitudinal
Follow-up: 1–4 m




Wyrwich et al. 2003
Chronic obstructive
pulmonary disease
Delphi method Patient change scenarios and
SF36 data
12.5
Wyrwich et al. 2004
Coronary artery disease/
congestive heart failure






Cella et al. 2002
Cancer (n = 2,583)
Cross-sectional
Longitudinal
3 d - 12 m
Performance status, haemoglobin level,
response to treatment
3 (6 %) 3
Cella et al. 2005
RA (n = 271)
Longitudinal
Follow-up: 24 w




Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons















Table 3 Studies/substudies (n = 60) with reported MIDs for fatigue scales, subscales or single fatigue items. Study design and population are shown along with estimation
method (Continued)
Lai et al. 2011
SLE (n = 254)
Longitudinal
Follow-up: 12–52 w




Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons
8.3 (16 %) 6.8 5.2
Reddy et al. 2007
Cancer (n = 194)
Longitudinal
Follow-up: 8 d
Global Benefit Score (7 step) 10
FACT-An Fatigue
(0–80)
Patrick et al. 2003









Schwartz et al. 2002
Cancer (n = 103)
Longitudinal
Follow-up: 2 d




Bedard et al. 2013b
Cancer (n = 276)
Longitudinal
Follow-up: 1 m
Overall QoL 24.5 19.7 (1 SEM)
6–15
(0.2–0.5 SD)
Bedard et al. 2014





13.6–17.3 1.8 (1 SEM)
6.7–16.8
(0.2–0.5 SD)





Global rating of change
(7-step but categorized into 3)
13.5 8.6
Maringwa et al. 2011a
Brain cancer (n = 941)
Cross-sectional
and longitudinal
WHO Performance Status and MMSE 12.4 8.9 10.0 (1 SEM)
Maringwa et al. 2011b




PS and weight change
14.1 5.7 11 (1 SEM)
Zeng et al. 2012
Cancer (n = 93)
Longitudinal
Follow-up: 1 m





Lasch et al. 2009
MDD (n = 379)
Longitudinal
Follow-up: 8 w
Clinician rated tool (7-step) on severity
and improvement
E/F: 11.9 (12 %)





Schünemann et al. 2005
Chronic obstructive
pulmonary disease
Systematic review CRQ data from5 studies, patient global
ratings anchors and distributions based
MIDs
0.5–0.6 (8–10 %) 0.47–0.54
(1 SEM)
0.5
Wyrwich et al. 2003
Chronic obstructive
pulmonary disease
Delphi method Patient change scenarios and CHQ data 2
CHQ
(4–28)
Wyrwich et al. 2004
Coronary artery disease/
congestive heart failure
























Borghs et al. 2012
Epilepsy (n = 1,035)
Longitudinal
study of 3 RCTs
Follow-up: 12 w
Patient global impression of change
(PGIC)
Regression analysis






Colangelo et al. 2009
SLE (n = 202)
Longitudinal
Follow-up: 7.5 m
Self-rated health (5 step) 13.9 9.1




Follow-up: ≤ 16 m
Self-rated health (5 step) 6.2 15.2
Kwok & Pope 2010
PsA (n = 200)
Longitudinal
Follow-up: ≤12 m
Self-rated health (5 step) 8.2 3.6





Self-rated health (5 step) 10.0 3.8
Wells et al. 2007




HAQ, Patient Global assessment of
disease and pain
6.7–17 (7–17 %) 10
Wheaton & Pope
2010 SpA (n = 140)
Longitudinal
Follow-up: 5 m




Khanna et al. 2008
RA (n = 307)
Longitudinal
Follow-up: 5.9 m






Goligher et al. 2008
SLE (n = 80)
Cross-sectional GRS (7-step)
Paired comparisons
1.3 (13 %) 0.3 1.5
Pouchot et al. 2008
RA (n = 61)
Cross-sectional GRS (7-step)
Paired comparisons
2.0 (20 %) 0.9 1.5
Schwartz et al. 2001
Cancer (n = 103)
Longitudinal
Follow-up: 2 d




Bedard et al. 2013a
Cancer (n = 421)
Longitudinal
Follow-up: 4–12 w
Well-being 0.1–1.3 1.0–1.8 0.1 (1 SEM)
0.5–1.4
(0.2–0.5 SD)
Reddy et al. 2007
Cancer (n = 194)
Longitudinal
Follow-up: 8 d
Global Benefit Score (7 step) 4
ITP-PAC
(0–100)
Mathias et al. 2009
ITP (n = 125)
Longitudinal
Follow-up: 4 w
Global assessment of change items
(15-step)















Table 3 Studies/substudies (n = 60) with reported MIDs for fatigue scales, subscales or single fatigue items. Study design and population are shown along with estimation
method (Continued)




Yost et al. 2011















Yost et al. 2011











GRS (7-step) = Global rating scale with 7 response categories: Much more fatigue, Somewhat more fatigue, A little bit more fatigue, About the same fatigue, A little bit less fatigue, Somewhat less fatigue, and Much
less fatigue
Paired comparisons = Participants rated their fatigue in relation to another participant















well as distribution based methods [31]. MID ranged be-
tween 3.0 and 4.2 and a triangulated MID-value of 4 was
suggested.
Vitality scale (VT) of the medical outcome study SF-36
health survey (SF-36), score 0–100
Eight studies [26, 33, 35, 46, 54, 56, 59, 60] determined
MIDs for the VT scale of the SF-36 using different de-
signs and diagnostic groups; longitudinal with patient-
and/or clinician rated anchors, cross-sectional using
patient-rated anchors and systematic reviews using com-
bined study data and expert panels. The MIDs ranged
from 7.3 to 11.3 for improvement, 11.9 to 18.3 for wors-
ening and 3.5 to 20, for all those with a global change
and 4.2 to 18.8 for a triangulated MID.
FACIT fatigue scale (FACIT-Fatigue), score 0–52
Six cross-sectional or longitudinal studies [28, 29, 33, 38,
46, 48] reported MID estimates derived in patients with
cancer, SLE, or RA using patient or clinician-rated anchors.
In these studies, MIDs varied from 3 to 8.3 irrespective of
direction of change, 2.8 to 6.8 for improvement and 5.2 to
9.1 for deterioration. Two of the studies [29, 38] combined
various distribution-based approaches (SEM, SD and ES),
resulting in MIDs ranging between 2.2 and 6.8, and pre-
sented triangulated MIDs ranging between 3 and 6.
FACT-an fatigue subscale (FACT-An Fatigue), score 0–80
One longitudinal study [45] estimated a MID for im-
provement of 4.2 in cancer patients using haemoglobin
level as a clinical anchor and regression analysis to
calculate MID.
Profile of mood states short form fatigue subscale (POMS-F),
score 0–28
One longitudinal study reported MIDs for the POMS-F
using a sample of cancer patients undergoing chemo-
therapy [51]. A global MID of 5.6 points was determined
as well as separate MIDs for improvement (2.1 points)
and deterioration (5.7 points).
European organization for research and treatment of
cancer quality of life questionnaire core 30 (EORTC
QLQ-30)—fatigue scale, score 0–100
Six cross-sectional and longitudinal studies [24, 25, 36,
40, 41, 62] reported MIDs derived in a variety of cancer
diagnoses. MIDs were reported as 11.4 to 17.3 points for
improvement and 5.7–24.5 points for deterioration.
Distribution-based MIDs ranged from 3.0 to 19.7.
Sleep impact scale (SIS), energy/fatigue and mental fatigue
subscales, score 0–100
One longitudinal study [39] using a clinician-rated an-
chor and a distribution-based method to assess change
at 8-week follow-up, reported MIDs derived in patients
with major depressive disorder (MDD). The anchor-
based approach yielded a MID of 11.9 for the Energy/Fa-
tigue subscale, whereas the distribution-based MID was
8.7. The corresponding MIDs for the Mental Fatigue
subscales were 13.3 and 10.6, respectively.
Chronic respiratory questionnaire (CRQ), score 1–7
Two systematic reviews [52, 59] used CRQ data from
earlier studies to determine MIDs for the CRQ/Fatigue
subscale and triangulated MIDs of 0.5 and 2 were
proposed. One of the reviews estimated MIDs between
0.5–0.6 for global change and distribution-based MIDs of
0.47–0.54 [52].
Chronic heart failure questionnaire (CHQ), score 4–28
One systematic review using CHQ data and an expert
panel proposed a MID for the CHQ/Fatigue subscale
of 3–4 irrespective of direction and a triangulated
MID of 3 [60].
Quality of life inventory in Epilepsy (QOLIE-31), energy/fatigue
subscale, score 0–100
One longitudinal study used 3 randomised controlled
trials to examine MID for the QOLIE-31/Energy/fatigue
subscale [27]. A MID of 7.5 was defined using a patient
rating of change and regression analysis. Distribution-
based MIDs ranged between 5.4 and 9.4.
Visual analogue scale (VAS), score 0–100 or 0–10
Six longitudinal studies [30, 32, 37, 53, 57, 58] derived
MIDs for the VAS 0–100 and one [34] for the VAS 0–10
in a variety of diagnostic groups. MIDs for the VAS-100
ranged from 1.4 to 13.9 for improvement and 3.6 to 15.2
for deterioration, while the global change varied between
6.7 and 17. One study [57] determined a triangulated
MID of 10 using the Delphi method. MIDs for the VAS-
10 ranged between 0.8 to 1.1 for improvement and 1.1
to 1.3 for worsening, and were derived from three differ-
ent anchors and at different follow-up times in three dif-
ferent diagnostic groups (RA, SLE and cancer) [34].
Global rating scale (GRS), score 0–10
MIDs for the single item GRS scale were determined in
SLE, RA and cancer patients in two cross-sectional stud-
ies [33, 46] and one longitudinal study [51], all using a
patient global rating scale as an anchor. Global MIDs
ranged from 1.1 to 2.0, while MIDs for improvement
were 0.3 to 0.9 and for deterioration 1.5.
Edmonton symptom assessment system (ESAS) fatigue item,
score 0–10
Two longitudinal cancer studies [23, 48] identified MIDs
for the fatigue item in the ESAS scale. MIDs for
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improvement ranged from 0.1 to 4 and between 1.0 and
1.8 for worsening of fatigue. Distribution-based MIDs
ranged from 0.1 to 1.4.
Immune thrombocytopenic Purpura—Patient assessment
questionnaire, (ITP-PAC) fatigue subscale, score 0–100
One longitudinal study [42] assessed MIDs using patient
impression of change for the ITP-PAC/Fatigue subscale.
Global change was defined as 15.0 or as an effect size of
0.57.
PROMIS fatigue item bank scales
17-item PROMIS fatigue (fatigue-17) and 7-item PROMIS
Fatigue (Fatigue-7), score 17–85 and 7–35
One study [61] derived MIDs for both the PROMIS
Fatigue-17 and Fatigue-7 in patients with cancer. The
study used both cross-sectional and longitudinal data as
well as anchor-based and distribution-based methods.
Distribution-based MIDs were reported as effect sizes.
For the Fatigue-17, the ES ranged from 0.34–0.79 and
0.27–0.52 for cross-sectional and longitudinal designs,
respectively. Corresponding effect sizes for the Fatigue-7
were 0.24–0.76 and 0.24–0.51. Triangulated raw score
MIDs ranged from 4.0 to 8.0 for the Fatigue-17 and 2.0
to 3.0 for the Fatigue-7 while t-score MIDs varied be-
tween 2.5 to 4.5 for the Fatigue-17 and 3.0 to 5.0 for the
Fatigue-7.
Discussion
This systematic review identified 41 studies reporting
MIDs for 28 fatigue PROMs or subscales measuring fa-
tigue, yielding a total of 60 studies or substudies estimat-
ing MID. It is important to note that there are many
more fatigue PROMs available today than the 28 re-
ported here. For example, a critical review of fatigue
PROMs from 2009 [8] identified 39 such PROMs; how-
ever, only 11 of these overlapped with PROMs in our re-
view. This suggests that there are roughly 56 or more
fatigue PROMs currently represented in the literature.
Considering the importance attributed to MIDs for
interpreting the meaningfulness of change in PROM
scores [9, 63], it is somewhat surprising that MIDs are
available for only about half of all published fatigue
PROMs. Moreover, few PROMs had MIDs that were de-
termined in more than two studies and diagnostic
groups, and more than half of the PROMs had MIDs
that were derived in only one diagnostic group. Important
exceptions were the SF-36 Vitality scale (>8 diagnostic
groups/8 studies; the FACIT-Fatigue scale (4 diagnoses/6
studies); the EORTC QLQ-C30 Fatigue subscale (6 cancer
diagnoses/6 studies); and the VAS-100 Fatigue (6 diagno-
ses/6 studies). Considering that these scales are some of
the most widely used and oldest PROMs in use today it is
unsurprising that greater research attention has focused
on determining MIDs for these scales; however, it is note-
worthy that so few separate studies reported MIDs for
commonly used generic fatigue PROMs, such as the MFI,
FSS, FIS and FAS.
Previous research has highlighted considerable variabil-
ity in MID values as a function of estimation method,
population and context [14, 18, 19], suggesting the im-
portance of considering such factors when appraising the
appropriateness of published MIDs for use in clinical re-
search and practice. In line with this, substantial variation
was observed in MID values for individual fatigue PROMs
in this review. For example, MIDs for the SF-36 Fatigue
scale ranged from as low as 4.2 to as high as 20.0 points
(0–100 point scale) in studies varying in methodologies, an-
chors, diagnostic groups and direction of change assessed.
Similarly, MIDs for the VAS-100 Fatigue scale ranged from
1.4 to 17. MIDs for the cancer-specific EORTC QLQ-C30
fatigue scale also varied between 1.8 and 24.5 points (0–100
scale) and those for the FACIT-Fatigue scale ranged
between 6 and 16 (converted to percent), see Table 3.
This wide variation in MIDs for individual fatigue
scales suggests the importance of understanding how
any particular MID was derived and of applying this
knowledge when appraising its appropriateness for
interpreting changes in fatigue scores.
MID estimation methods varied considerably in the
identified studies and substudies. However, in accordance
with recent recommendations regarding methods for MID
estimation [14], nearly all studies applied an anchor-based
approach, where at least one anchor was used. Patient glo-
bal change ratings were by far the most common anchor,
but even clinician-reported and clinical anchors were
implemented. Where more than one anchor was applied
either a range of values was generally reported or, as rec-
ommended [14, 63, 64], values were often triangulated to
a single or smaller range of MIDs. Distribution-based
methods were used in about a third of the studies and
only in conjunction with anchor-based approaches. A few
studies used a Delphi method (Table 3).
In the studies using several anchors to determine MID
values, global MID ranges varied within single studies
from as little as two points (percent scores), in relation
to the FACIT-Fatigue scale using patient-based anchors
[29], to about 20 points for the TOI-F [28] using patient,
clinician and clinical anchors. Interestingly, two studies
reporting MIDs for the SF-36 Vitality scale, using the
same diagnostic group (RA) but different anchors, yielded
two distinct ranges of MIDs. In the study by Kosinski
et al. [35], using patient and physician global assessments
as anchors, MIDs ranged from 4.9–11.1, whereas a range
of 11.0–20.0 was reported by Ward et al. [56] using the
HAQ, CES-D and the SF-36 health transition item.
Neither of these studies triangulated the range of values to
a single MID or smaller range of values and hence these
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wide ranges of MIDs are arguably of questionable practical
value for interpreting change in fatigue in RA patients as
measured with the SF-36 Vitality.
Triangulation was used in 17 substudies, of which 10
used more than two anchors. This method has been rec-
ommended for consolidating MIDs derived from differ-
ent methods to a single or small range of MID values
[14]. However, it has been criticized [19] since it may in
practice involve the need to converge widely disparate
MIDs derived using different estimation methods and di-
verse anchors, which often represent very different
stakeholder perspectives. An example of a MID triangu-
lated from a wide range of MIDs is the TOI-F [28] where
a MID range of 4.4–24.6 (percent scores) was triangu-
lated to 5.0. Where MID ranges are smaller, the value
and applicability of the triangulated MID may be more
immediately apparent. For example, Schünemann et al.
[52] reported a MID range for the CRQ of 6.7–8.5
(percent scores), derived from patient anchors, a system-
atic review and distribution-based methods, which was tri-
angulated to a MID of 6.7.
A second factor known to influence variation in MID
values is the patient population in which the MID is de-
termined. Variation by diagnostic group is exemplified
by comparing MIDS from two studies, each using the
same estimation method (7-step global rating scale) and
study design (cross-sectional) but different diagnostic
groups [33, 46]. One of the studies [33] determined
MIDs for seven different fatigue PROMs in patients with
SLE and the other [46] did the same in patients with
RA. Comparison of the global MIDs for the SLE and RA
patients, shown in Table 3, shows consistently smaller
MIDs for SLE versus RA across all seven PROMs. It
is noteworthy that most PROMs had MIDs that were
determined in only one patient population and the
relevance of these MIDs for use in other patient groups
thus remains unclear.
A third factor influencing variation in MID values is
the context within which the MID is determined. Con-
text issues concern, for example, characteristics of the
patient population, e.g., such as baseline state [65], dis-
ease severity [66], and direction of change [13, 20], as
well as study design and intervention. For example, pa-
tients with baseline scores indicating more severe fatigue
may value magnitudes of change in fatigue differently
than those with less severe fatigue. Corroborating previ-
ous research finding, MIDs for improvement differed
from those for deterioration in all identified studies.
MIDs tended to be larger for deterioration than im-
provement, except in the EORTC QLQ-30 and VAS
Fatigue item. MIDs for improvement were consistently
smaller than global MIDs.
A strength of this study is that reported MIDs for fa-
tigue scales or subscales were systematically compiled
and described. Assessment for inclusion or exclusion
and data extraction from included studies was done in-
dependently by two authors (ÅN and AD). A limitation
is that the search period was restricted to studies from
2000 onwards and search strings for the many variations
on MID was also limited and therefore some studies
reporting MIDs for fatigue scales may not have been
captured in the literature searches. Another limitation is
that the description of the study designs and results had
to be summarized and simplified in tables and informa-
tion could be lost. Therefore, when evaluating MIDs the
original study/studies should be consulted.
Conclusions
MIDs vary substantially by estimation method, patient
population and context both across and within fatigue
PROMs. In light of this variation, published MIDs
should be applied judiciously, after carefully considering
their applicability to characteristics of the study in ques-
tion. The information provided in this paper may serve
to aid researchers and clinicians in making informed de-
cisions regarding the appropriateness of published MIDs
for their particular study and patients.
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